MedTrace Logo

HDDO-1614 Bio Equivalence Study

NCT03382314 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-02-26

No results posted yet for this study

Summary

A randomized, open-label, single-dose, crossover study

Conditions

Interventions

COMBINATION_PRODUCT

HDDO-1614

* Combination drug (Bazedoxifene + Cholecalciferol) * Incrementally modified drug * Not market authorized product

DRUG

Bazedoxifene / Cholecalciferol

Co- Administration of Bazedoxifene and Cholecalciferol

Sponsors & Collaborators

  • Hyundai Pharmaceutical Co., LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-16
Primary Completion
2017-12-21
Completion
2018-01-05

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03382314 on ClinicalTrials.gov